Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3540378 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3540378 (Part A) | EXPERIMENTAL | Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC). |
| LY3540378 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC. |
| LY3540378 (Part C) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC in Japanese Participants. |
| LY3540378 (Part D) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC in Chinese Participants. |
| Placebo (Part A, B, C & D) | PLACEBO_COMPARATOR | Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3540378 | DRUG | Administered IV or SC. |
| Placebo | DRUG | Administered IV or SC. |
Inclusion Criteria: * Overtly healthy males or females, as determined by medical history and physical examination. * Body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²) * For Part C, participants should be first generation Japanese origin. * For Part D, participan...
LY3540378 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, studied in healthy participants. The drug is not approved and remains under investigation.
LY3540378 is being studied in healthy participants as part of early clinical development. Its intended therapeutic use has not been established, as it is still in Phase 1 trials.
LY3540378 is developed by Eli Lilly and Company, a biopharmaceutical company traded on the stock exchange under the ticker LLY.
LY3540378 is in Phase 1 clinical development. A Phase 1 study in healthy participants has been completed, and the drug remains investigational.
LY3540378 has one completed Phase 1 trial, NCT04768855, titled "A Study of LY3540378 in Healthy Participants." The trial enrolled 134 participants in the United States and Singapore.
LY3540378 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development, with a completed study in healthy participants.